Safety and Efficacy of R-PAD Regimen in Patients with Severe Multiple Center Idiopathic Castleman Disease: A Retrospective Case Series

To report the efficacy and safety of R-PAD regimen in four cases of patients with idiopathic multiple center Castleman disease (iMCD).

The clinical data of the four cases of patients met the diagnostic criteria of severe iMCD were collected, the efficacy and safety of R-PAD regimen were analyzed. The detail of R-PAD regimen is as follow: Rituximab 375mg/m2 day 1; Bortezomib 1.3mg/m2 day 1, 8, 15; Liposomal adriamycin 15mg/m2 day 1; Dexamethasone 20mg day 1-4, 9-12, 17-20. Four weeks as a course, total 4-6 courses were administered. And then, thalidomide and predinisone or dexamethasone were administered as maintenance.

Total 4 cases were enrolled, 3 female and 1 male. The median age was 45 years-old. One case was with TAFRO，1 case idiopathic plasmacytic lymphadenopathy, 1 case NOS and 1 NOS with hemophagocytic lymphohistiocytosis. The complete remission rate were 100%，and no 3 grade above adverse events were found.

R-PAD regimen might be a useful protocol as an induction regimen for patients with severe iMCD.

No relevant conflicts of interest to declare.